(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.68%) $83.28
(-1.16%) $1.619
(0.00%) $2 347.30
(-0.04%) $27.53
(0.20%) $923.90
(-0.08%) $0.934
(-0.03%) $11.02
(-0.12%) $0.799
(0.00%) $92.17
1.06% € 100.52
Live Chart Being Loaded With Signals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...
Stats | |
---|---|
Tagesvolumen | 823.00 |
Durchschnittsvolumen | 592.00 |
Marktkapitalisierung | 174.42B |
EPS | €0 ( 2024-04-17 ) |
Nächstes Ertragsdatum | ( €0 ) 2024-07-17 |
Last Dividend | €0.510 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 33.51 |
ATR14 | €0 (0.00%) |
Abbott Laboratories Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Abbott Laboratories Finanzdaten
Annual | 2023 |
Umsatz: | €40.11B |
Bruttogewinn: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2023 |
Umsatz: | €40.11B |
Bruttogewinn: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2022 |
Umsatz: | €43.65B |
Bruttogewinn: | €24.51B (56.15 %) |
EPS: | €3.99 |
FY | 2021 |
Umsatz: | €43.08B |
Bruttogewinn: | €24.54B (56.97 %) |
EPS: | €4.00 |
Financial Reports:
No articles found.
Abbott Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.470 (N/A) |
€0.470 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.510 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | €22.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.9 | -- |
Div. Sustainability Score | 4.40 | |
Div.Growth Potential Score | 7.33 | |
Div. Directional Score | 5.87 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NGLB.DE | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
ABR.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
YCP.DE | Ex Dividend King | 2023-09-27 | Bi-Monthly | 0 | 0.00% | |
G24.DE | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
PND.F | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
BAC.DE | Ex Dividend Knight | 2023-10-09 | Quarterly | 0 | 0.00% | |
HXCK.DE | Ex Dividend Junior | 2023-05-11 | Sporadic | 0 | 0.00% | |
SIX2.DE | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
CMC.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
KTF.DE | Ex Dividend Knight | 2023-06-29 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.140 | 1.500 | 7.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.474 | -1.000 | 5.26 | -5.26 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 22.04 | 1.000 | 2.95 | 2.95 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 8.77 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.552 | 1.000 | 4.13 | 4.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.84 | 8.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.43 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 9.18 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.971 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.474 | 1.500 | 5.26 | -5.26 | [0 - 1] |
pegRatioTTM | 6.47 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 7.33 |
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.